Objective Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. Methods A systematic...
OBJECTIVE: -methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated rapid antidepressant effects in patients with TRD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence for efficacy and safety of racemic ketamine and to provide recommendations for its use in clinical practice. METHODS: A systematic review was conducted with...
Background: This study investigated variations in psychic and somatic anxiety during and after completion of MBCT compared to baseline in patients diagnosed with BD. Secondary variables considered were sleep quality and quality of life, as well as depressive and manic symptoms. Methods: HAMD-29, HAMD-7 and YMRS were administered at baseline (n=34), and every two weeks until the end of the...